Back to Authors

Herrera, Alex F.

https://orcid.org/0000-0002-9665-7415

A5030788778 | I1301076528

Mayo Clinic

City Of Hope National Medical Center

Citations 66

INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 177-178

10.1002/hon.134_2629

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation

JAMA Oncology | February 28, 2019 | Volume: 5 | Issue: 5 | Pages: 715

10.1001/jamaoncol.2018.6278 | PMID 30816957

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940

10.1182/bloodadvances.2018018531 | PMID 29685953

Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Blood | December 11, 2017 | Volume: 131 | Issue: 11 | Pages: 1183-1194

10.1182/blood-2017-10-811224 | PMID 29229594

Key Points BV and Nivo were well-tolerated in patients with R/R HL, with less than 10% of patients treated with systemic steroids for immune-related AEs. The complete response rate was 61% (82% objective response rate), and patients were able to undergo stem cell transplant without adverse impact.
CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2

INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 85-86

10.1002/hon.2437_73